<DOC>
	<DOCNO>NCT02682277</DOCNO>
	<brief_summary>The polyglucosamine , specification L112 , medical device clinical trial use weight reduction moderately obese participant follow long term treatment last 12 month . The rationale study show overweight reduce take 2 time daily 2 tablet main meal .</brief_summary>
	<brief_title>Efficacy Polyglucosamine Long Term Treatment</brief_title>
	<detailed_description>Two group subject compare . A comparable diet condition , consist 10 % reduction caloric intake follow , accord questionnaire base weekly number serving . No modification physical activity request . One group take polyglucosamine tablet group placebo tablet least 12 month . It known , polyglucosamine fat binder act physical-chemical manner , positive charge fiber bound negative charge dietary fat complex unable pas gut wall body naturally excrete , hence energy available . Therefore , medical device show measurable reduction body weight .</detailed_description>
	<criteria>BMI &gt; 30 &lt; 35 waist circumference 88 cm woman great 102 men pregnancy breastfeed alcohol abuse drug abuse drug addiction inability fulfill criterion trial protocol cancer diseases malignant tumor preexistence chronic intestinal disease know hypersensitivity reaction crustacean</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>obesity</keyword>
	<keyword>body weight</keyword>
	<keyword>overweight</keyword>
	<keyword>weight loss</keyword>
	<keyword>polyglucosamine</keyword>
	<keyword>L112</keyword>
	<keyword>caloric restriction</keyword>
	<keyword>physical activity</keyword>
</DOC>